Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

The HIV pipeline

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mechanisms of action in the pipeline.

References

  1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. WHO [online], (2013).

  2. Araújo, L. A. L. & Almeida, S. E. M. HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition. Viruses 5, 595–604 (2013).

    Article  Google Scholar 

  3. GBI research. HIV therapeutics in major developed market to 2019. GBIHC328MR (2014).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angel Wong.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wong, A. The HIV pipeline. Nat Rev Drug Discov 13, 649–650 (2014). https://doi.org/10.1038/nrd4364

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4364

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research